TY - JOUR
T1 - Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa
T2 - Implications for dose optimization
AU - the ERACE-PA Global Study Group
AU - Gill, Christian M.
AU - Aktaş, Elif
AU - Alfouzan, Wadha
AU - Bourassa, Lori
AU - Brink, Adrian
AU - Burnham, Carey Ann D.
AU - Canton, Rafael
AU - Carmeli, Yehuda
AU - Falcone, Marco
AU - Kiffer, Carlos
AU - Marchese, Anna
AU - Martinez, Octavio
AU - Pournaras, Spyros
AU - Seifert, Harald
AU - Thabit, Abrar K.
AU - Villegas, Maria Virginia
AU - Westblade, Lars F.
AU - Nicolau, David P.
AU - Wille, Julia
AU - Rezende, Thais Teles Freitas
AU - Cekin, Zuhal
AU - Malkocoglu, Gulsah
AU - Gijón, Desirèe
AU - Tarakmeh, Layla Abdullah
AU - Chu, Chun Yat
AU - Opperman, Christoffel Johannes
AU - Tootla, Hafsah Deepa
AU - Moodley, Clinton
AU - Coetzee, Jennifer
AU - Vourli, Sophia
AU - Dimopoulos, George
AU - Attallah, Dalya M.
AU - Tiseo, Giusy
AU - Leonildi, Alessandro
AU - Giordano, Cesira
AU - Barnini, Simona
AU - Menichetti, Francesco
AU - Di Pilato, Vincenzo
AU - Codda, Giulia
AU - Vena, Antonio
AU - Giacobbe, Daniele Roberto
AU - Satlin, Michael
AU - Cardona, Armando
AU - Curtis, Lauren
AU - Fang, Ferric
AU - Thomson, Gina
AU - Thomson, Ken
N1 - Publisher Copyright:
© 2021 American Society for Microbiology.
PY - 2021/11
Y1 - 2021/11
N2 - The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.
AB - The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.
KW - Carbapenem resistance
KW - Cefepime
KW - Ceftazidime
KW - Pharmacodynamics
KW - Pharmacokinetics
KW - Pseudomonas aeruginosa
UR - http://www.scopus.com/inward/record.url?scp=85117522008&partnerID=8YFLogxK
U2 - 10.1128/AAC.01204-21
DO - 10.1128/AAC.01204-21
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34398670
AN - SCOPUS:85117522008
SN - 0066-4804
VL - 65
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 11
M1 - e01204-21
ER -
